Rs 98 to Rs 583: This pharma stock has surged nearly 500% in the last two years!

The returns generated by the company are 5 times the returns delivered by the S&P BSE 500 index, of which the company is a part.

Laurus Labs Ltd, an S&P BSE 500 company, has delivered multibagger returns to its shareholders in the last two years. During this period, the company’s share price has appreciated by 490%, from Rs 98.87 on 5 May 2020 to Rs 583.65 on 29 April 2022. An investment of Rs 1 lakh in this stock two years ago would have turned to Rs 5.9 lakh today!

Laurus Labs Ltd, one of the S&P BSE 200 companies, is a leading research-driven pharmaceutical manufacturing company in India. It has grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, AntiDiabetics, Anti-Asthma and Gastroenterology.

Its facilities have been certified and approved by WHO, USFDA, NIP Hungary, PMDA, KFDA and BfArM. The company works with all the top 10 generic pharmaceutical companies in the world. It sells its APIs in 56 countries. Its major focus areas include anti-retroviral, Hepatitis C and Oncology drugs. The company has undertaken dedicated R&D in areas that have significant growth potential. It has filed 315 patents of which it owns 177 patents. The company has commercialised over 60 products since its inception across three distinct business units: Generics API, Generics FDF and Synthesis.

In the recent quarter Q4FY22, on a consolidated basis, the company’s topline increased by 38.50% QoQ to Rs 1424.83 crore. Similarly, the bottom line increased by 49.64% QoQ to Rs 231.90 crore.

The company is currently trading at a TTM PE of 37.96x, as against the industry PE of 32.85x. Overall, in FY22, the company delivered an ROE & ROCE of 24.84% and 30.05%, respectively.

At 2.50 pm, the shares of Laurus Labs Ltd were trading at Rs 593.50, an increase of 1.69% from the previous closing price of Rs 583.65 on BSE. The stock has a 52-week high & low of Rs 723.55 and Rs 433.20 respectively on BSE.